Literature DB >> 19836856

Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections.

Cassandra Moran1, Chelsea A Grussemeyer, James R Spalding, Daniel K Benjamin, Shelby D Reed.   

Abstract

We compared costs, length of stay, and mortality between adults with Candida albicans and Candida glabrata bloodstream infections. Early evidence of C glabrata, as defined by a positive culture within 2 days of admission, was associated with higher costs ($56,026 vs $32,810; P = .04) and longer hospital stays (19.7 vs 14.5 days; P = .05) compared with early evidence of C albicans. Mortality was similar between the groups. Copyright 2010 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 19836856      PMCID: PMC3319041          DOI: 10.1016/j.ajic.2009.06.014

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  10 in total

Review 1.  Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies.

Authors:  M E Falagas; K E Apostolou; V D Pappas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-07       Impact factor: 3.267

2.  The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.

Authors:  Theoklis E Zaoutis; Jesse Argon; Jaclyn Chu; Jesse A Berlin; Thomas J Walsh; Chris Feudtner
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

3.  The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

Authors:  A M Rentz; M T Halpern; R Bowden
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

4.  Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.

Authors:  J Nolla-Salas; A Sitges-Serra; C León-Gil; J Martínez-González; M A León-Regidor; P Ibáñez-Lucía; J M Torres-Rodríguez
Journal:  Intensive Care Med       Date:  1997-01       Impact factor: 17.440

5.  Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients.

Authors:  Susan L Davis; Jose A Vazquez; Peggy S McKinnon
Journal:  Ann Pharmacother       Date:  2007-03-20       Impact factor: 3.154

Review 6.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

7.  Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection.

Authors:  Michael J Klevay; Erika J Ernst; Jesse L Hollanbaugh; Joshua G Miller; Michael A Pfaller; Daniel J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2007-11-19       Impact factor: 2.803

8.  Time to blood culture positivity as a marker for catheter-related candidemia.

Authors:  Ronen Ben-Ami; Miriam Weinberger; Ruth Orni-Wasserlauff; David Schwartz; Avraham Itzhaki; Tzipora Lazarovitch; Edna Bash; Yuval Aharoni; Irina Moroz; Michael Giladi
Journal:  J Clin Microbiol       Date:  2008-05-14       Impact factor: 5.948

9.  Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs.

Authors:  Cassandra Moran; Chelsea A Grussemeyer; James R Spalding; Daniel K Benjamin; Shelby D Reed
Journal:  Pediatr Infect Dis J       Date:  2009-05       Impact factor: 2.129

10.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

  10 in total
  32 in total

1.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  Monitoring Phenotypic Switching in Candida albicans and the Use of Next-Gen Fluorescence Reporters.

Authors:  Corey Frazer; Aaron D Hernday; Richard J Bennett
Journal:  Curr Protoc Microbiol       Date:  2019-02-12

Review 3.  Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Authors:  Marios Arvanitis; Theodora Anagnostou; Beth Burgwyn Fuchs; Angela M Caliendo; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

4.  Genetic Basis of Azole and Echinocandin Resistance in Clinical Candida glabrata in Japan.

Authors:  Hazim O Khalifa; Teppei Arai; Hidetaka Majima; Akira Watanabe; Katsuhiko Kamei
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

5.  Cost-Effectiveness Analysis of Multiplex PCR with Magnetic Resonance Detection versus Empiric or Blood Culture-Directed Therapy for Management of Suspected Candidemia.

Authors:  Brandon Walker; Margaret V Powers-Fletcher; Robert L Schmidt; Kimberly E Hanson
Journal:  J Clin Microbiol       Date:  2016-01-06       Impact factor: 5.948

6.  Identification of Components of the SUMOylation Machinery in Candida glabrata: ROLE OF THE DESUMOYLATION PEPTIDASE CgUlp2 IN VIRULENCE.

Authors:  Rahul Gujjula; Sangeetha Veeraiah; Kundan Kumar; Suman S Thakur; Krishnaveni Mishra; Rupinder Kaur
Journal:  J Biol Chem       Date:  2016-07-05       Impact factor: 5.157

7.  Genetic Analysis of Sirtuin Deacetylases in Hyphal Growth of Candida albicans.

Authors:  Guolei Zhao; Laura N Rusche
Journal:  mSphere       Date:  2021-05-05       Impact factor: 4.389

8.  A Candida albicans PeptideAtlas.

Authors:  Vital Vialas; Zhi Sun; Carla Verónica Loureiro y Penha; Montserrat Carrascal; Joaquín Abián; Lucía Monteoliva; Eric W Deutsch; Ruedi Aebersold; Robert L Moritz; Concha Gil
Journal:  J Proteomics       Date:  2013-06-26       Impact factor: 4.044

Review 9.  Candida Bloodstream Infections: Changes in Epidemiology and Increase in Drug Resistance.

Authors:  Fleischer Cn Kotey; Nicholas Tkd Dayie; Patience B Tetteh-Uarcoo; Eric S Donkor
Journal:  Infect Dis (Auckl)       Date:  2021-06-24

10.  Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia.

Authors:  Vinod Kumar; Shih-Chin Cheng; Melissa D Johnson; Sanne P Smeekens; Agnieszka Wojtowicz; Evangelos Giamarellos-Bourboulis; Juha Karjalainen; Lude Franke; Sebo Withoff; Theo S Plantinga; Frank L van de Veerdonk; Jos W M van der Meer; Leo A B Joosten; Pierre-Yves Bochud; Oscar Marchetti; John R Perfect; Ramnik Xavier; Bart Jan Kullberg; Cisca Wijmenga; Mihai G Netea
Journal:  Nat Commun       Date:  2014-09-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.